Table 3.
Univariate analysis for platelet engraftment at 1 year.
| Parameter | Engraftment rate (95% CI) | P value |
|---|---|---|
|
| ||
| UCB unit cryopreservation (years) | ||
| 0–2 | 75% (64–87) | |
| 2.1–4 | 72% (59–84) | |
| >4 | 76% (63–89) | 0.89 |
|
| ||
| TNC (×107/kg) | ||
| <2.5 | 62% (43–80) | |
| ≥2.5 | 76% (69–84) | 0.10 |
|
| ||
| CD34+ (×105/kg) | ||
| <2.5 | 74% (57–92) | |
| ≥2.5 | 75% (67–83) | 0.77 |
|
| ||
| Post thaw viability | ||
| <75% | 75% (66–85) | |
| ≥75% | 73% (62–85) | 0.67 |
|
| ||
| CFU-GM (×106/kg) | ||
| <5.0 | 72% (61–82) | |
| ≥5.0 | 82% (71–92) | <0.01 |
|
| ||
| HLA matching | ||
| 6/6 match | 81% (68–95) | |
| 5/6 or less | 72% (63–80) | 0.05 |
|
| ||
| ABO Match | ||
| Match | 69% (57–81) | |
| Minor mismatch | 74% (62–86) | |
| Major mismatch | 80% (67–93) | 0.63 |
|
| ||
| Conditioning regimen | ||
| Myeloablative | 74% (66–82) | |
| Reduced intensity | 76% (58–93) | 0.02 |
|
| ||
| Year of transplant | ||
| Prior to 2006 | 71% (60–81) | |
| 2006–2013 | 77% (67–87) | 0.04 |
|
| ||
| Recipient CMV | ||
| Positive | 70% (60–80) | |
| Negative | 78% (68–88) | 0.14 |
|
| ||
| Recipient gender | ||
| Male | 74% (65–84) | |
| Female | 74% (64–85) | 0.38 |
|
| ||
| Recipient age (years) | ||
| <18 | 76% (68–84) | |
| ≥18 | 64% (46–81) | 0.76 |
CFU-GM – colony forming unit granulocyte macrophage; CMV – cytomegalovirus; HLA – human leukocyte antigen; TNC – total nucleated cell; UCB – umbilical cord blood